Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

BACKGROUND: Immune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment following clinically significant irAEs is growing, the safety and efficacy are not yet well characterized. METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Abou Alaiwi, Sarah, Xie, Wanling, Nassar, Amin H, Dudani, Shaan, Martini, Dylan, Bakouny, Ziad, Steinharter, John A, Nuzzo, Pier Vitale, Flippot, Ronan, Martinez-Chanza, Nieves, Wei, Xiao, McGregor, Bradley A, Kaymakcalan, Marina D, Heng, Daniel Y C, Bilen, Mehmet A, Choueiri, Toni K, Harshman, Lauren C
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7057439/
https://ncbi.nlm.nih.gov/pubmed/32066646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000144
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars